Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ST. JUDE SURGEON TRAINING FOR TORONTO SPV STENTLESS PORCINE VALVE TO REACH OVER 100 U.S. PHYSICIANS BY YEAR-END, COMPANY SAYS; FDA APPROVES DEVICE NOV. 24

This article was originally published in The Gray Sheet

Executive Summary

St. Jude Medical hopes to train over 100 U.S. surgeons in the use of the Toronto SPV stentless porcine heart valve by the end of the year. Approved by FDA on Nov. 24 as a replacement for malfunctioning native or prosthetic aortic heart valves, the Toronto SPV is the first stentless tissue heart valve to reach the U.S. market.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009202

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel